摘要
肿瘤的免疫疗法在近年来取得了巨大的突破,肿瘤免疫微环境中的程序性死亡受体-1/程序性死亡配体-1(PD-1/PD-L1)通路是介导肿瘤免疫逃逸的重要途径,PD-1抑制剂的成功研发及初步临床运用揭示了其蕴含的巨大潜力。中医药是世界范围内治疗肿瘤的重要补充与替代医学手段之一,现有研究表明中医药可以改善机体免疫力,重塑肿瘤免疫微环境。该文重点对PD-1/PD-L1介导的免疫抑制机制进行回顾,并在总结了其在肿瘤微环境中发挥的作用,主要包括肿瘤微环境对PD-1/PD-L1表达的调控等内容,并对中药单体、复方在PD-1/PD-L1领域的研究及中药对调节性T细胞(Treg)细胞的调控现状进行了综述,以期为后续研究提供参考。
Tumour immunology has made a great breakthrough in recent years.The PD-1/PD-L1 pathway in tumour immune microenvironment is a vital way to mediate immune evasion of tumour.The successful research,development and preliminary clinical application of PD-1 inhibitors reveal their great charms.Traditional Chinese Medicine(TCM)is one of the important complementary and alternative therapies for cancer treatment.Current studies have indicated that TCM can improve the body immunity and remodel tumour immune microenvironment.Our study focuses on the review of PD-1/PD-L1-mediated immunosuppressive mechanisms,and to some extent summarizes the role played by the tumor microenvironment,mainly including the regulation of PD-1/PD-L1 expression by the tumor microenvironment,and also reviews the research of TCM monomer and compound in the field of PD-1/PD-L1 and the current status of TCM regulation on Treg cells,in order to provide reference for subsequent studies.
作者
陈芝强
綦向军
李泽云
陈国铭
吴金凤
孙玲玲
曹洋
林丽珠
CHEN Zhiqiang;QI Xiangjun;LI Zeyun;CHEN Guoming;WU Jinfeng;SUN Lingling;CAO Yang;LIN Lizhu(First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou 510405, China;Second Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou 510405, China;Department of Oncology, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, China;Project Team of Cancer, Evidence-Based Medicine Center of Chinese Medicine, Beijing 100000, China)
出处
《中国肿瘤外科杂志》
CAS
2021年第3期305-311,共7页
Chinese Journal of Surgical Oncology
基金
2019国家中医药管理局《中医药循证能力建设项目》(2019XZZX-ZL001)。
